Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Jardiance (empagliflozin) is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure; to reduce the risk of sustained decline in eGFR, end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease at risk of progression; to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease; and as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus.
• This summary is based on the review of 46 systematic review(s)/meta-analysis(es). ^[1-46]
• Empagliflozin (25 mg) increased hematocrit levels in T2DM patients, but canagliflozin 100 mg had the best effect on hematocrit, and canagliflozin 200 mg showed the best improvement in hemoglobin.
• SGLT2 inhibitors (dapagliflozin and empagliflozin) significantly improved 6-min walk distances in HFpEF patients. Empagliflozin also improved VO2peak in T2DM patients with chronic heart failure.
• Empagliflozin reduced cardiovascular events, including cardiovascular death, in patients with CVD and demonstrated benefits in reducing cardiovascular events and improving metabolic control.
• Empagliflozin significantly reduced the risk of cardiovascular death or hospitalization for HF in patients with HFrEF and improved left ventricular function.
• Both dapagliflozin and empagliflozin demonstrated favorable safety profiles with no significant side effects observed in heart failure patients.
• Empagliflozin was associated with an increased risk of reproductive tract infections and pollakiuria, whereas canagliflozin had an increased risk of lower limb amputations, which was not significant for empagliflozin.
• SGLT2 inhibitors, including empagliflozin, were associated with an increased risk of diabetic ketoacidosis (DKA), as noted in both observational studies and randomized clinical trials.
• There is no population type or subgroup information available in the reviewed studies.